In COPD, dual bronchodilation (LAMA/LABA) is generally considered the standard of care. If patients are prone to exacerbations, the addition of inhaled steroids (ICS) may be useful. But what about patients who achieve inadequate disease control despite these treatment options and who have an elevated blood eosinophil count (≥300 cells/µl)? For this subpopulation, dupilumab has been approved in the EU as an add-on, i.e. in addition to existing medication, since the end of June 2024.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- DOAK optimization, ABC pathway and lessons learned from the FXI/XIa pipeline
Stroke prevention for atrial fibrillation 2025
- From symptom to diagnosis
Abdominal pain – Hernias
- "Survey of Health, Ageing and Retirement in Europe" (SHARE)
Analysis of polypharmacy in ≥65-year-olds
- New perspectives for clinics and research
Ageing, cellular senescence and Parkinson’s disease
- From early intervention to individualization
The new guidelines at a glance
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- Focus on prevention
Colorectal cancer screening – an update
- COPD therapy